Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis

open access

Article Outline

1. 1. Introduction
2. 2. Materials and methods
   1. 2.1. End-points
      1. 2.1.1. Subgroup analysis
   2. 2.2. Statistical analysis
3. 3. Results
   1. 3.1. Transfusion
   2. 3.2. Thrombotic events
   3. 3.3. Overall mortality
   4. 3.4. Failures disease
4. 4. Discussion
5. 5. Conclusion
6. Authors’ contributions
7. Conflicts of interest
8. References
9. Biography

Highlights

• •
  Gynecological cancers are the one at highest risk of anemia.
• •
  Data on erythropoiesis-stimulating agents (ESAs) benefit and risks are discordant.
• •
  We found significant reduction in transfusion rates.
• •
  We found no detrimental effect on overall mortality and failures disease.